This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Daniel Haller, MD; Philip S. Schein, MD
University of Pennsylvania School of Medicine Philadelphia

JAMA. 1986;255(3):321-322.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

We read with considerable interest and some concern the article by Cullinan et al¹ comparing the efficacy of three chemotherapeutic regimens, in particular the FAM combination (fluorouracil, Adriamycin [doxorubicin hydrochloride], and mitomycin C) in advanced gastric and pancreatic cancer. Although we agree that the literature does not fully support the use of doxorubicin-containing regimens for patients with pancreatic cancer, we believe that Cullinan's report is deficient in describing the potential benefits of combination chemotherapy in gastric cancer reported in other published trials.

The authors fail to cite the later (1980) Georgetown University experience utilizing FAM chemotherapy, in which 62 patients with advanced, measurable gastric cancer were treated and a 42% response rate, which was shown to correlate well with increased survival, was obtained.²

The comparative trial of four chemotherapy combinations from the Gastrointestinal Tumor Study Group (1982) is not referenced.³ This study, in which . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?